Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

196P - Targeting ESR1 in breast cancer treatment: Repurposing of statins


16 Sep 2021


ePoster Display


Eva Rahman Kabir


Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687


E.R. Kabir, N. Nausheen, N. Mustafa

Author affiliations

  • Pharmacy, Brac University, 1212 - Dhaka/BD

Abstract 196P


Management of breast cancer has significantly changed in the last few years, witnessing the advent of more and more therapeutic approaches. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases according to GLOBOCAN, 2020. With the significant increase in the incidence of breast cancer, targeted therapies are in urgent need for treatment. Aberrantly high levels of Estrogen Receptor alpha (ESR1) are found in more than 70% of all breast cancers and found to be a crucial therapeutic target for treating ESR1 positive breast cancer. A systematic in silico study was carried out to find out some potential statin drug candidates that may be used in breast cancer treatment.


Molecular docking of statins and the reference drug (brilanestrant) with ESR1, superimposition of selected drugs with ESR1-reference, comparison of interactions of reference and candidate drugs with the protein (ESR1) and pharmacokinetic properties of the chosen drugs were evaluated to come up with the most promising statin drug candidate for breast cancer treatment. Targeting ESR1, screening of statin drugs was carried out via several in silico approaches.


Brilanestrant had a binding affinity of -8.6 kcal/mol. The drugs with the highest binding affinities were then superimposed with the reference. Based on the superimposition results, drug-protein interactions were visualized in Discovery Studio. Among them, pitavastatin, rosuvastatin and simvastatin had four common amino acids with the ESR1-reference interactions. The pharmacokinetic properties of both the reference and selected candidates were assessed using QikProp. The predicted human oral absorption of brilanestrant was 79.35%. Simvastatin, lovastatin and mevastatin showed excellent human oral absorption (100%). They also showed excellent intestinal permeability compared to the reference and did not penetrate the CNS or the blood brain barrier as suggested by the CNS, logBB and PSA values.


The study indicates that the drugs, simvastatin, lovastatin and mevastatin could be effective drugs in breast cancer treatment. However, further studies including in vitro and in vivo tests will be required to investigate their safety, efficacy and dosing profiles.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.